{
    "clinical_study": {
        "@rank": "35314", 
        "arm_group": [
            {
                "arm_group_label": "Group 1", 
                "description": "A: Rosuvastatin\nB: Ezetimibe\nC: Rosuvastatin and Ezetimibe A \u2192 B \u2192 C"
            }, 
            {
                "arm_group_label": "Group 2", 
                "description": "C \u2192 A \u2192 B"
            }, 
            {
                "arm_group_label": "Group 3", 
                "description": "B \u2192 C \u2192 A"
            }, 
            {
                "arm_group_label": "Group 4", 
                "description": "C \u2192  B \u2192 A"
            }, 
            {
                "arm_group_label": "Group 5", 
                "description": "B \u2192 A \u2192 C"
            }, 
            {
                "arm_group_label": "Group 6", 
                "description": "A \u2192  C \u2192 B"
            }
        ], 
        "brief_summary": {
            "textblock": "The purpose of this study is to investigate the pharmacokinetic drug interactions between\n      Rosuvastatin and Ezetimibe in Healthy Male Subjects"
        }, 
        "brief_title": "Investigating the Pharmacokinetic Drug Interactions Between Rosuvastatin and Ezetimibe", 
        "completion_date": {
            "#text": "November 2014", 
            "@type": "Anticipated"
        }, 
        "condition": "Healthy", 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Healthy male volunteer, age 19~45 years\n\n          -  The result of Body Mass Index(BMI) is not less than 19 kg/m2 , no more than 28 kg/m2\n\n          -  Subject who has the ability to comprehend the study objectives, contents and the\n             property of the study drug before participating in the trial.\n\n        Exclusion Criteria:\n\n          -  Presence of medical history or a concurrent disease that may interfere with treatment\n             and safety assessment or completion of this clinical study\n\n          -  History of relevant drug allergies or clinically significant hypersensitivity\n             reaction."
            }, 
            "gender": "Male", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "45 Years", 
            "minimum_age": "19 Years", 
            "sampling_method": "Non-Probability Sample", 
            "study_pop": {
                "textblock": "Healthy male volunteer"
            }
        }, 
        "enrollment": {
            "#text": "24", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "April 29, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02127320", 
            "org_study_id": "HM-ROZE-101"
        }, 
        "intervention_browse": {
            "mesh_term": [
                "Rosuvastatin", 
                "Ezetimibe"
            ]
        }, 
        "is_fda_regulated": "No", 
        "lastchanged_date": "April 29, 2014", 
        "location": {
            "contact": {
                "email": "mdhslim@gmail.com", 
                "last_name": "Hyeong-Seok Lim, MD PhD", 
                "phone": "02-3010-4613"
            }, 
            "facility": {
                "address": {
                    "city": "Seoul, Korea, Republic of", 
                    "country": "Korea, Republic of"
                }, 
                "name": "Asan Medical Center"
            }, 
            "investigator": {
                "last_name": "Hyeong-Seok Lim, MD PhD", 
                "role": "Principal Investigator"
            }, 
            "status": "Not yet recruiting"
        }, 
        "location_countries": {
            "country": "Korea, Republic of"
        }, 
        "number_of_groups": "6", 
        "official_title": "A Randomized, Open Label Crossover Study to Investigate the Pharmacokinetic Drug Interactions Between Rosuvastatin and Ezetimibe in Healthy Male Subjects", 
        "overall_contact": {
            "email": "jajung@hanmi.co.kr", 
            "last_name": "Jin-A Jung, Ph.D"
        }, 
        "overall_official": {
            "affiliation": "Asan Medical Center", 
            "last_name": "Hyeong-Seok Lim, MD PhD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Not yet recruiting", 
        "oversight_info": {
            "authority": "Korea: Ministry of Food and Drug Safety", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "September 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": [
            {
                "measure": "Rosuvastatin AUC\u03c4,ss", 
                "safety_issue": "No", 
                "time_frame": "1D 0h(predose), 9D 0h, 10D 0h, 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 11D 0h, 12D 0h, 13D 0h"
            }, 
            {
                "measure": "Rosuvastatin Cmax,ss", 
                "safety_issue": "No", 
                "time_frame": "1D 0h(predose), 9D 0h, 10D 0h, 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 11D 0h, 12D 0h, 13D 0h"
            }, 
            {
                "measure": "Ezetimibe Cmax,ss", 
                "safety_issue": "No", 
                "time_frame": "1D 0h(predose), 9D 0h, 10D 0h, 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 11D 0h, 12D 0h, 13D 0h"
            }, 
            {
                "measure": "Ezetimibe AUC\u03c4,ss", 
                "safety_issue": "No", 
                "time_frame": "1D 0h(predose), 9D 0h, 10D 0h, 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 11D 0h, 12D 0h, 13D 0h"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02127320"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Rosuvastatin Tmax,ss", 
                "safety_issue": "No", 
                "time_frame": "1D 0h(predose), 9D 0h, 10D 0h, 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 11D 0h, 12D 0h, 13D 0h"
            }, 
            {
                "measure": "Rosuvastatin t1/2\u03b2", 
                "safety_issue": "No", 
                "time_frame": "1D 0h(predose), 9D 0h, 10D 0h, 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 11D 0h, 12D 0h, 13D 0h"
            }, 
            {
                "measure": "Ezetimibe Tmax,ss", 
                "safety_issue": "No", 
                "time_frame": "1D 0h(predose), 9D 0h, 10D 0h, 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 11D 0h, 12D 0h, 13D 0h"
            }, 
            {
                "measure": "Ezetimibe t1/2\u03b2", 
                "safety_issue": "No", 
                "time_frame": "1D 0h(predose), 9D 0h, 10D 0h, 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 11D 0h, 12D 0h, 13D 0h"
            }
        ], 
        "source": "Hanmi Pharmaceutical Company Limited", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Hanmi Pharmaceutical Company Limited", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "June 2014", 
        "study_design": "Observational Model: Case-Crossover, Time Perspective: Cross-Sectional", 
        "study_type": "Observational", 
        "verification_date": "April 2014"
    }
}